The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment
Abstract
Abrupt interruption or cessation of selective serotonin reuptake inhibitor (SSRI) treatment may result in discontinuation or treatment interruption symptoms. Recent reports suggested these symptoms occur more frequently with shorter half-life SSRIs. Previous studies indicated a 5-8-day treatment interruption resulted in fewer discontinuation-emergent adverse events in fluoxetine-treated patients than in paroxetine-treated patients. This study examines the effects of shorter treatment interruption (3-5 days), as would occur if patients miss just a few doses of medication. Patients successfully treated for depression with fluoxetine or paroxetine underwent treatment interruption in a double-blind fashion. Treatment interruption-emergent symptoms were assessed using the Discontinuation-Emergent Signs and Symptoms checklist. Other assessments included the Montgomery-Asberg Depression Rating Scale, Clinical Global Impressions-Severity scale and a social functioning questionnaire. Of 150 patients enrolled, 141 completed the study. Following treatment interruption, fluoxetine-treated patients experienced fewer treatment interruption-emergent events than did paroxetine-treated patients. The paroxetine treatment group also experienced significant increases in depressive symptoms, clinical global severity scores and difficulty in social functioning; the fluoxetine treatment group did not. These results are consistent with reports suggesting abrupt interruption of treatment with paroxet…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After treatment interruption, discontinuation symptoms, as measured through the DESS, were more frequently reported by patients treated with paroxetine (p < 0.001) and sertraline (p < 0.001) than by those receiving fluoxetine.”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [22]
In the citing paper
“When treatments were compared, individuals treated with paroxetine reported the greatest number of DESS symptoms compared to those treated with sertraline (p < 0.05) and fluoxetine (p < 0.001).”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [22]
In the citing paper
“Further, during discontinuation, anxiety, depression, somatic symptoms, and hostility were significantly greater in the paroxetine and sertraline groups (p < 0.001 in all conditions) than in the fluoxetine arm.”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [22]
In the citing paper
“In conclusion, among patients with MDD, the average mean DESS score was 5.7 (SD = 7.36) for those who discontinued treatment with paroxetine [22,38,39,45] , whereas for escitalopram [41,45] it ranged from 2.4 to 3.2, and in both studies investigating fluoxetine discontinuation [22,38] , it was 0.2 (SD = 3.86).”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [22]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Delgado, P. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810170011002 · Cited by 924
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303
Thomas, D. R., Nelson, D. R., & Johnson, A. M. (1987) · Psychopharmacology · doi:10.1007/bf00179933 · Cited by 251
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209 · cited 3×
“SSRI discontinuation syndrome is characterized by a cluster of somatic and psychological symptoms, including disequilibrium, gastrointestinal symptoms, influenza-like symptoms, sensory disturbances, sleep disturbances, anxiety and irritability (Coupland et al., 1996; Price et al., 1996; Schatzberg et al., 1997; Zajeck…”
BackgroundEmergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
Fava, M., Mulroy, R., Alpert, J., Nierenberg, A. A., & Rosenbaum, J. F. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1760 · Cited by 198
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181
PRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171
Antidepressant withdrawal phenomena.
Dilsaver, S. C., & Greden, J. F. (1984) · PubMed · Cited by 157
Research works printed but not linked: 3
- Benazzi, 1998b, J Psychiatry Neurosci, 23, 94
- Dominguez, 1995, Pharmacotherapy, 15, 778
- Schatzberg, 1997, J Clin Psychiatry, 58, 5
Cited by
Dubocovich, M. L., Delagrange, P., Krause, D. N., Sugden, D., Cardinali, D. P., & Olcese, J. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002832 · Cited by 621
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Metadata
- Authors
- Judge, R., Parry, M. G., Quail, D., & Jacobson, J. G.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Jacobson, J.G.
- Venue
- International Clinical Psychopharmacology
- Published
- 2002-09
- Volume
- 17
- Issue
- 5
- Pages
- 217-225
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1971247978
- Semantic Scholar
- 3f5e052c5277cf4a5350770f5614a9d5021fdf76
- Cited by
- 87
- References
- 25
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 10 · 2012: 2
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- discontinuation symptoms, treatment interruption, fluoxetine, paroxetine, selective serotonin reuptake inhibitors, depression, medication adherence, social functioning, adverse drug reactions
- MeSH terms
- Adult, Depressive Disorder, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Prospective Studies, Psychiatric Status Rating Scales, Social Behavior, Substance Withdrawal Syndrome, Selective Serotonin Reuptake Inhibitors, Paroxetine, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. https://app.cochat.ai/papers/10.1097/00004850-200209000-00002
- The paper
- Judge, R., Parry, M. G., Quail, D., & Jacobson, J. G. (2002). Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200209000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.